Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Choate says it advised Merida on an acquisition by Lilly worth up to $2.875 billion
Choate said it advised longtime client Merida Biosciences on its acquisition by Eli Lilly and Company in a transaction valued at up to $2.875 billion. The firm said Merida develops precision autoantibody degraders intended to treat autoimmune and allergic diseases and identified its intellectual property team supporting the deal.
Key points
- Choate said Merida’s lead program was in Phase 1 development.Choate
- The firm said the program targeted Graves’ disease and thyroid eye disease.Choate
- Choate identified Charles Lyon and Dana Daukss as members of its team.Choate
- The firm said Stephany Foster and Tracy Yang also worked on the transaction.Choate